Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Shire Rises As US FDA Approves Takhzyro Drug

Fri, 24th Aug 2018 10:39

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Shire, up 2.6%. The Irish pharmaceutical company said the US Food & Drug Administration has approved its Takhzyro drug to treat a rare genetic disease. The disease, hereditary angioedema, causes attacks of swelling in different parts of the body and can be life-threatening. Approval from the FDA follows a phase III study of 125 patients in which Takhzyro reduced monthly attacks by, on average, 87% in patients when compared with a placebo. Antofagasta, up 2.0%. RBC Capital upgraded the Chilean copper miner to Outperform from Sector Perform. ----------FTSE 100 - LOSERS----------Berkeley Group, down 2.3%, Barratt Developments, down 1.9%, Persimmon, down 1.7%, Taylor Wimpey, down 1.2%. The housebuilders were lower amid a decline in UK mortgage approvals in July. The number of mortgages approved in July fell to 39,584 from 40,330 in June. Economists had forecast approvals to rise to 40,650, data from UK Finance showed. "Housebuilders have taken a knock as a double whammy of lower new approved mortgages and a five-month low in mortgage lending weighed on the sector," IG Group analyst Chris Beauchamp said. Midcap peers McCarthy & Stone, Bovis Homes and Bellway were down 2.1%, 1.4% and 1.2%, respectively. ----------FTSE 250 - WINNERS----------Ted Baker, up 2.0%. Peel Hunt raised the high street fashion retailer to Add from Hold. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Henry Boot, up 4.5%. The construction company said interim profit and revenue both rose in an "impressive" first half performance. For the six months to June, Henry Boot's pretax profit was up 16% to GBP26.2 million, while revenue rose slightly to GBP196.2 million from GBP195.4 million a year prior. Its net asset value per share increased by 18% to 217 pence. Henry Boot is paying an interim dividend to shareholders of 3.20p, from 2.80p a year prior. The company said it has seen "consistent" levels of demand across all of its businesses in the first half of 2018, particularly in housing development land. ----------OTHER MAIN MARKET AND AIM - LOSERS----------Bahamas Petroleum, down 63%. The oil and gas explorer said its exclusivity agreement with a major international oil company will terminate at the end of the month. The unnamed international company has notified Bahamas that it will not be extending the agreement, which has been in place since the start of May, past next Friday and will cease exclusivity payments. Bahamas said it has recommenced broader asset-based discussions with third parties. These will continue alongside the ongoing non asset-based discussions which surround the funding of its first exploration well.----------
More News
24 Aug 2018 11:54

LONDON MARKET MIDDAY: Stocks Up; Powell To Make Jackson Hole Debut

LONDON (Alliance News) - Stocks in London were marginally higher at midday on Friday ahead of a highly anticipated speech from the head of the US Federal Reserve.With US-China trade talks demoting a

Read more
24 Aug 2018 08:38

LONDON MARKET OPEN: Stocks Mixed, Shire Rises After Drug Approval

LONDON (Alliance News) - Stock prices in London were mixed early Friday, as markets await US Federal Reserve Chair Jerome Powell's speech in Wyoming later in the day. In the large cap index rose

Read more
24 Aug 2018 08:06

FDA gives nod to Shire's TAKHZYRO treatment

(Sharecast News) - Shire announced on Friday that, following priority review, the US Food and Drug Administration (FDA) has approved the 'TAKHZYRO' (lanadelumab-flyo) injection for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older.

Read more
24 Aug 2018 07:41

LONDON MARKET PRE-OPEN: Slightly Lower Call Ahead Of Powell Speech

LONDON (Alliance News) - Stock prices in London are seen lower on Friday ahead of US Federal Reserve Chair Jerome Powell's speech later during the day, while in a quiet day for UK company news In

Read more
13 Aug 2018 10:31

WINNERS & LOSERS SUMMARY: Chemring Says Fatal Accident To Hurt Profit

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------BAE up 0.8%. a

Read more
13 Aug 2018 09:21

Shire Partner Shionogi Files New Drug Application For Intuniv In Japan

LONDON (Alliance News) - Irish drugmaker Shire PLC said on Monday its Japanese partner Shionogi & Co Ltd has submitted a new drug application for the manufacture and marketing of Intuniv in is

Read more
13 Aug 2018 07:51

Shire and Shionogi apply to expand ADHD treatment to adults

(Sharecast News) - Shire and Shionogi have applied to expand the use in Japan of co-developed drug Intuniv to treat adults for attention deficit hyperactivity disorder.

Read more
31 Jul 2018 12:51

TOP NEWS: Shire Income Up In 2nd-Quarter Ahead Of Takeover By Takeda

LONDON (Alliance News) - Irish biotechnology company Shire PLC on Tuesday posted a more than doubled pretax income in the second quarter, ahead of its upcoming takeover by Takeda Pharmaceutical Co

Read more
31 Jul 2018 12:12

Shire posts 4 pct rise in Q2 earnings ahead of sale to Takeda

LONDON, July 31 (Reuters) - Shire, the London-listed pharmaceutical group being bought by Japan's Takeda, reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to just

Read more
31 Jul 2018 12:08

Shire's quarterly sales rise on immunology demand

(Sharecast News) - Shire reported healthy sales growth in the second quarter as the biotech company pressed ahead with its acquisition by Takeda of Japan.

Read more
31 Jul 2018 08:05

UPDATE 1-Takeda posts weakest Q1 profit in three years

* Q1 operating profit Y98.9 bln vs Y195 bln a year earlier * Takeda booked gains from asset sales a year earlier (Adds details) TOKYO, July 31 (Reuters) - Japan's Takeda Co Ltd a

Read more
25 Jul 2018 07:00

RPT-ANALYSIS-Buy yen in crisis? Not this year

* Yen weakest G10 currency this month despite global turbulence * Investors doubt BOJ can reduce stimulus aggressively * Japanese purchases of foreign equities highest in nearly Bond

Read more
24 Jul 2018 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 25 July GlaxoSmithKlineHalf Year Results (at 1200 BST)Vodafone GroupTrading 26

Read more
24 Jul 2018 15:08

ANALYSIS-Buy yen in crisis? Not this year

* Yen weakest G10 currency this month despite global turbulence * Investors doubt BOJ can reduce stimulus aggressively * Japanese purchases of foreign equities highest in nearly Bond

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.